preEMBER: A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer

Condition: Breast Cancer

Sponsor: Eli Lilly and Company

Full Title
Protocol J2J-MC-JZLL: A Phase 2, Open-label Study Evaluating Imlunestrant in Premenopausal Women with
Estrogen Receptor-Positive, HER2-Negative Breast Cancer

Study Treatment
Oral SERD Imlunestrant vs standard endocrine therapy

Eligibility/Info
Cohort 1: Stage I-III ER+, HER2- breast cancer with plans for curative surgery but not history of systemic therapy. 

Cohort 2: Early stage ER+, HER2- breast cancer that has been resected and completed curative treatment followed by 2 - 4.5 years of adjuvant endocrine therapy. 

Contact
For more information about this or any other study, please contact the NYCBS Research Department:
Email: ResearchRecruitment@nycancer.com
Telephone: 631-675-5075
HALO Messaging App: "Research Team"

Locations
Babylon Medical Oncology
Central Park Medical Oncology
Eastchester Cancer Center
Lake Success Medical Oncology
Nostrand Medical Oncology
Patchogue Medical Oncology
Port Jefferson Medical Oncology
Port Jefferson Station Medical Oncology
Riverhead Medical Oncology

Go To Trial Homepage